Global Statistics

All countries
266,200,412
Confirmed
Updated on December 6, 2021 9:41 am
All countries
238,072,488
Recovered
Updated on December 6, 2021 9:41 am
All countries
5,273,249
Deaths
Updated on December 6, 2021 9:41 am

Global Statistics

All countries
266,200,412
Confirmed
Updated on December 6, 2021 9:41 am
All countries
238,072,488
Recovered
Updated on December 6, 2021 9:41 am
All countries
5,273,249
Deaths
Updated on December 6, 2021 9:41 am

Transparency by drug companies, surveillance by journalists, important in vaccine news |

Pfizer chairman and CEO announced in a Pfizer company news releases: “Today is a big day for science and humanity.” In that PR press release – but only in that format – Pfizer announced preliminary results “a vaccine efficacy rate above 90%, at 7 days after the second dose.”

That’s all we know – what Pfizer has to say about its own vaccine. The data has not been published or released to the public – only that 90% figure.

Regarding security, Pfizer’s corporate news release states, “no serious security issues were observed.” Since no raw data has been released, we don’t know how “serious” is defined.

Pfizer undertook the project: “We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks.”

In the early story, STAT does a great job covering warnings and limitations. Quote:

“… Important information about vaccines is not yet available. There is no information yet whether the vaccine prevents severe cases, the kind that can lead to hospitalization and death.

There is no information yet whether it prevents people from carrying the virus that causes Covid-19, SARS-CoV-2, without symptoms.

“If that headline really fits, it’s huge. It was much better than I expected and it would make a huge difference,” said Ashish Jha, dean of the School of Public Health at Brown University. He cautions, however, that it is always difficult to evaluate science through press releases and that researchers need to see the full results. He noted that side effects are something to watch out for, because even if there are no serious long-term complications, people feeling sick for a day or two may cause some people to hesitate to take the vaccine.

The story of how the data is analyzed does not seem the least bit dramatic. Pfizer, seeing an opportunity to help fight the pandemic and demonstrating its research prowess, made a decision that most likely always made its study the first Covid-19 vaccine to generate data.

The New York Times reports:

Pfizer … has released only a handful of details from its clinical trials.

Independent scientists have warned against hyping up early results before long-term safety and efficacy data are collected. And no one knows how long vaccine protection can last.

(A senior VP of Pfizer) sought to distance the company from Operation Warp Speed ​​and the politics of the presidency, noting that the company – unlike other vaccine pioneers – did not take federal money to help pay for research and development.

Vox is clear to include important caveats even with Twitter post restrictions:

That level of scrutiny, especially with one of the first news stories to come out of the gate, is critical. Not everyone lives up to that standard.

When BuzzFeed hit the headlines, “Pfizer’s coronavirus vaccine is more than 90% effective, preliminary data says,” Journalist Paul Thacker suggested a fix for the title – “Pfizer’s Coronavirus Vaccine More Than 90% Effective, Says Incomplete Data That Has Not Been Validated By Independent Experts.” The story uses the phrase “very promising.” Strunk and White, di Style Element, it is recommended to eliminate unnecessary words. “Absolutely” is not necessary. And “promising” is one I’ve had for a long time seven words you shouldn’t use in medical news.

CNN has no independent perspective in the first story.

Fox News is too promising, stated: “FOX Business looks at key data points investors and consumers should know.” But no critical data has been released – only Pfizer’s announcement of “90% effective.”

Of course, much of the second wave of news has celebrated the jump in Pfizer stock, and in the stock market in general, in response to Pfizer’s PR news release.

Scientist James Heathers tweeted:

Just last week, professors Jennifer Miller, Joseph Ross and Michelle Mello published in STAT, “Much more transparency needed for COVID-19 vaccine trials. Their closing words: “Transparency will help ensure this achievement is believable.” It’s up to you to judge whether today’s Pfizer PR press release lives up to those standards of trust and transparency.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

spot_imgspot_img
spot_img

Hot Topics

Related Articles